<DOC>
	<DOC>NCT00275210</DOC>
	<brief_summary>To evaluate the FOLFOX regimen versus LV5FU2 in the adjuvant treatment of stage II and III colon cancer. Primary objective: Disease Free Survival (DFS) Secondary objective: Overall Survival (OS), safety (including long term toxicity)</brief_summary>
	<brief_title>MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Main selection criteria: Histologically proven stage Dukes " B2 " (stage II: T3T4 N0 M0) and " C " (stage III: any T N12 M0) colon carcinoma. The inferior pole of the tumor must be above the peritoneal reflection (&gt; 15 cm from the anal margin)· Complete resection of the primary tumor without gross or microscopic evidence of residual disease Treatment within 7 weeks following surgery Age 1875 years old ECOG PS £ 2 No prior chemo, immuno or radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Oxaliplatin</keyword>
	<keyword>Chemotherapy,adjuvant</keyword>
	<keyword>Colonic Neoplasms</keyword>
</DOC>